Eton Pharmaceuticals (NASDAQ:ETON) Shares Break Above 50 Day Moving Average – Here’s What Happened

Eton Pharmaceuticals, Inc. (NASDAQ:ETON)’s share price passed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $54.80 and traded as high as $58.59. Eton Pharmaceuticals shares last traded at $56.46, with a volume of 1,269,987 shares.

Trending Headlines about Eton Pharmaceuticals

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Q3 product sales reached a record $57.9 million, up 158% year over year. Eton reported diluted GAAP EPS of $1.06 and non-GAAP EPS of $0.50, and said it exceeded a $200 million annualized revenue run rate five quarters ahead of schedule. Eton Q3 results
• Positive Sentiment: Management raised its 2026 revenue outlook to more than $175 million, from more than $145 million, and lifted its adjusted EBITDA margin outlook to above 40%, from above 35%. The stronger forecast reinforces expectations for continued growth and improving profitability. Eton earnings and guidance
• Positive Sentiment: Canaccord Genuity and HC Wainwright both raised their price targets to $80 and maintained Buy ratings, signaling confidence in Eton’s prospects. Canaccord Genuity rating HC Wainwright rating
• Neutral Sentiment: Eton announced preliminary results from an ET-700 pilot study assessing copper absorption inhibition and gastrointestinal tolerability. The brief report does not provide enough detail to judge the findings’ significance for the pipeline. ET-700 pilot study update

Analysts Set New Price Targets

A number of research firms have weighed in on ETON. Zacks Research raised shares of Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 12th. Craig Hallum restated a “buy” rating and issued a $78.00 price target on shares of Eton Pharmaceuticals in a research report on Thursday, October 15th. HC Wainwright boosted their price target on shares of Eton Pharmaceuticals from $70.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday. Weiss Ratings raised shares of Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research note on Tuesday, September 22nd. Finally, B. Riley Financial reiterated a “buy” rating and set a $70.00 price objective (up from $40.00) on shares of Eton Pharmaceuticals in a research report on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $77.00.

Eton Pharmaceuticals Trading Up 19.7%

The firm’s 50-day moving average price is $54.80 and its 200 day moving average price is $36.46. The company has a market cap of $1.61 billion, a price-to-earnings ratio of 37.39 and a beta of 0.89. The company has a current ratio of 1.52, a quick ratio of 1.30 and a debt-to-equity ratio of 0.41.

Eton Pharmaceuticals (NASDAQ:ETON) last released its earnings results on Thursday, November 5th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.19. The company had revenue of $57.93 million for the quarter, compared to the consensus estimate of $41.98 million. Eton Pharmaceuticals had a net margin of 35.35% and a return on equity of 144.74%. As a group, equities analysts expect that Eton Pharmaceuticals, Inc. will post 1.13 EPS for the current year.

Insider Buying and Selling at Eton Pharmaceuticals

In other news, Director Paul V. Maier sold 50,000 shares of the stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the transaction, the director owned 59,745 shares of the company’s stock, valued at $3,529,137.15. This represents a 45.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider David Krempa sold 4,166 shares of the firm’s stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $55.07, for a total value of $229,421.62. Following the completion of the sale, the insider owned 43,381 shares of the company’s stock, valued at approximately $2,388,991.67. This represents a 8.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 79,166 shares of company stock valued at $4,809,672. Insiders own 16.49% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Hilton Head Capital Partners LLC acquired a new stake in Eton Pharmaceuticals in the third quarter valued at approximately $26,000. Sterling Capital Management LLC raised its position in shares of Eton Pharmaceuticals by 845.7% during the third quarter. Sterling Capital Management LLC now owns 889 shares of the company’s stock worth $46,000 after purchasing an additional 795 shares during the period. Toth Financial Advisory Corp acquired a new position in shares of Eton Pharmaceuticals during the second quarter worth approximately $43,000. USA Financial Formulas bought a new position in shares of Eton Pharmaceuticals in the 3rd quarter worth $62,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Eton Pharmaceuticals in the 3rd quarter worth $75,000. 27.86% of the stock is owned by institutional investors and hedge funds.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications.

Eton’s commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate.